EB FlevoResearch B.V.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• COPD2 trials
• Asthma1 trial
• Chronic kidney disease1 trial
• Obesity1 trial
• Stroke1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Completed2 trials
• Recruiting2 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Chiesi Farmaceutici S.p.A.1 trial
• Eli Lilly & Co.1 trial
• Novo Nordisk A/S1 trial
• UCB Biopharma SRL1 trial

Running trials

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· Phase 2· UCB Biopharma SRL· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma

  2025-522640-41-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source